Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 14, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 51
- −8 vs. Q2 2024
- Portfolio value
- $293.2M
- +$5.86M (+2.0%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| Biohaven LtdG1110E907 | CALL | 348,778 | $17.4M | 5.9% | +348,778 | New | – |
| SRPTSarepta Therapeutics, Inc. | COM | 120,000 | $15.0M | 5.1% | +65,000+118.2% | Added | History |
| NVONovo Nordisk A S | ADR | 110,000 | $13.1M | 4.5% | +110,000 | New | History |
| BPMCBlueprint Medicines Corp | COM | 140,000 | $12.9M | 4.4% | +100,000+250.0% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 135,000 | $12.1M | 4.1% | −15,000−10.0% | Reduced | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 350,000 | $11.5M | 3.9% | +115,000+48.9% | Added | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 750,000 | $10.0M | 3.4% | −175,000−18.9% | Reduced | History |
| CGONCG Oncology, Inc. | COM | 250,000 | $9.43M | 3.2% | −10,000−3.8% | Reduced | History |
| ROIVRoivant Sciences Ltd. | SHS | 800,000 | $9.23M | 3.1% | −200,000−20.0% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 80,000 | $9.14M | 3.1% | −70,000−46.7% | Reduced | History |
| VKTXViking Therapeutics, Inc. | COM | 140,000 | $8.86M | 3.0% | +45,000+47.4% | Added | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 450,000 | $8.66M | 3.0% | +100,000+28.6% | Added | History |
| JANXJanux Therapeutics, Inc. | COM | 190,000 | $8.63M | 2.9% | +140,000+280.0% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 52,500 | $7.84M | 2.7% | −34,221−39.5% | Reduced | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 150,000 | $7.67M | 2.6% | −90,000−37.5% | Reduced | History |
| SLNOSoleno Therapeutics Inc | COM | 150,000 | $7.57M | 2.6% | −150,000−50.0% | Reduced | History |
| TGTXTG Therapeutics, Inc. | COM | 310,000 | $7.25M | 2.5% | −190,000−38.0% | Reduced | History |
| RZLTRezolute, Inc. | COM NEW | 1,474,995 | $7.15M | 2.4% | +53,494+3.8% | Added | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 375,000 | $6.78M | 2.3% | −225,000−37.5% | Reduced | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 128,411 | $6.47M | 2.2% | −171,589−57.2% | Reduced | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 535,000 | $6.39M | 2.2% | −15,000−2.7% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 215,000 | $6.13M | 2.1% | −45,000−17.3% | Reduced | History |
| INSMINSMED Inc | COM PAR $.01 | 75,000 | $5.47M | 1.9% | +10,000+15.4% | Added | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 195,000 | $5.20M | 1.8% | +195,000 | New | History |
| REPLReplimune Group, Inc. | COM | 450,000 | $4.93M | 1.7% | 00.0% | Unchanged | History |
| BBIOBridgeBio Pharma, Inc. | COM | 175,000 | $4.46M | 1.5% | +35,000+25.0% | Added | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 2,150,000 | $4.32M | 1.5% | +900,000+72.0% | Added | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 78,842 | $4.13M | 1.4% | −38,546−32.8% | Reduced | History |
| ANNXAnnexon, Inc. | COM | 650,000 | $3.85M | 1.3% | +340,000+109.7% | Added | History |
| KRROKorro Bio, Inc. | COM | 110,000 | $3.68M | 1.3% | +10,000+10.0% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 100,000 | $3.59M | 1.2% | +100,000 | New | History |
| ARVNArvinas, Inc. | COM | 145,000 | $3.57M | 1.2% | +70,000+93.3% | Added | History |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | COM NEW | 160,000 | $3.30M | 1.1% | −15,000−8.6% | Reduced | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 300,000 | $3.13M | 1.1% | 00.0% | Unchanged | History |
| NUVBNuvation Bio Inc. | COM CL A | 1,350,000 | $3.09M | 1.1% | +200,000+17.4% | Added | History |
| SVRASavara Inc | COM | 725,000 | $3.07M | 1.0% | −325,876−31.0% | Reduced | History |
| TNYATenaya Therapeutics, Inc. | COM | 1,500,000 | $2.90M | 1.0% | +150,000+11.1% | Added | History |
| RGNXREGENXBIO Inc. | COM | 265,000 | $2.78M | 0.9% | +95,000+55.9% | Added | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 500,000 | $2.64M | 0.9% | +500,000 | New | History |
| ABSIAbsci Corp | COM | 550,000 | $2.10M | 0.7% | +550,000 | New | History |
| NGNENeurogene Inc. | COM | 50,000 | $2.10M | 0.7% | −20,000−28.6% | Reduced | History |
| CAPRCapricor Therapeutics, Inc. | COM NEW | 125,000 | $1.90M | 0.6% | +125,000 | New | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 65,000 | $1.87M | 0.6% | −70,000−51.9% | Reduced | History |
| SMMTSummit Therapeutics Inc. | COM | 85,000 | $1.86M | 0.6% | +85,000 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 60,000 | $1.76M | 0.6% | −190,237−76.0% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 75,000 | $1.71M | 0.6% | −512,708−87.2% | Reduced | History |
| PRQRProQR Therapeutics N.V. | SHS EURO | 887,700 | $1.62M | 0.6% | −12,300−1.4% | Reduced | History |
| ATYRaTYR PHARMA INC | COM NEW | 800,000 | $1.41M | 0.5% | 00.0% | Unchanged | History |
| LRMRLarimar Therapeutics, Inc. | COM | 200,000 | $1.31M | 0.4% | +200,000 | New | History |
| ENGNenGene Therapeutics Inc. | COM | 160,898 | $1.06M | 0.4% | −259,433−61.7% | Reduced | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 325,000 | $1.05M | 0.4% | +325,000 | New | History |
Options (3)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q2 2024 (18)
Positions held at the end of Q2 2024 that are gone from this filing.
| Security | Class | Shares in Q2 2024 | Value in Q2 2024 | % of portfolio in Q2 2024 | History |
|---|---|---|---|---|---|
| BHVNBiohaven Ltd. | COM | 490,000 | $17.0M | 5.9% | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 22,500 | $5.47M | 1.9% | History |
| ACADAcadia Pharmaceuticals Inc | COM | 225,000 | $3.66M | 1.3% | History |
| CABACabaletta Bio, Inc. | COM | 370,899 | $2.77M | 1.0% | History |
| CYTKCytokinetics Inc | COM NEW | 33,200 | $1.80M | 0.6% | History |
| ELEVElevation Acquisition Group Inc. | COM | 600,000 | $1.62M | 0.6% | History |
| KRYSKrystal Biotech, Inc. | COM | 8,500 | $1.56M | 0.5% | History |
| WVEWave Life Sciences, Inc. | SHS | 200,000 | $998.0K | 0.3% | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 35,000 | $909.6K | 0.3% | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 225,000 | $769.5K | 0.3% | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 10,000 | $684.9K | 0.2% | History |
| MGNXMacrogenics Inc | COM | 150,000 | $637.5K | 0.2% | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 375,000 | $607.5K | 0.2% | History |
| PTCTPTC Therapeutics, Inc. | COM | 19,000 | $581.0K | 0.2% | History |
| RVNCRevance Therapeutics, Inc. | COM | 225,000 | $578.3K | 0.2% | History |
| NTLAIntellia Therapeutics, Inc. | COM | 25,000 | $559.5K | 0.2% | History |
| ANTXAN2 Therapeutics, Inc. | COM | 219,331 | $471.6K | 0.2% | History |
| CTMXCytomX Therapeutics, Inc. | COM | 300,000 | $366.0K | 0.1% | History |